Clinical Trials Browser

Phase 2/3 × encorafenib × 90 days × Clear all

NCT05710406 2026-01-26

Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer

Phase 2/3 Active not recruiting

Gastrointestinal

Colonic Neoplasms